This is an open label, dose escalation Phase I single institution pilot study for relapsed
and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the
completion of dose escalation and after establishment of the MTD or recommended dose of
CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of
CC-486 in relapsed/refractory patients.